We serve Chemical Name:2-methoxy-1,3-bis(methylsulfanyl)propane CAS:31805-84-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-methoxy-1,3-bis(methylsulfanyl)propane
CAS.NO:31805-84-2
Synonyms:2-methoxy-1,3-bis-methylsulfanyl-propane;1,3-Bis(methylthio)-2-methoxypropane;MFCD00026040;EINECS 250-815-2;1,3-BIS-(METHYLTHIO)-2-METHOXYPROPANE
Molecular Formula:C6H14OS2
Molecular Weight:166.30500
HS Code:2930909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:242.5ºC at 760mmHg
Density:1.024g/cm3
Index of Refraction:1.497
PSA:59.83000
Exact Mass:166.04900
LogP:1.72740
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-methoxy-1,3-bis-methylsulfanyl-propane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-BIS-(METHYLTHIO)-2-METHOXYPROPANE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00026040 Use and application,1,3-BIS-(METHYLTHIO)-2-METHOXYPROPANE technical grade,usp/ep/jp grade.
Related News: A new case of coronavirus has been reported in the United Arab Emirates, the country’s fifth, the Ministry of Health and Prevention announced on Saturday. 2-methoxy-1,3-bis(methylsulfanyl)propane manufacturer Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. 2-methoxy-1,3-bis(methylsulfanyl)propane supplier China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. 2-methoxy-1,3-bis(methylsulfanyl)propane vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 2-methoxy-1,3-bis(methylsulfanyl)propane factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.
